Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Is there a role for radiation to the primary mediastinal disease in metastatic thymic neuroendocrine carcinoma with the primary as the only residual disease after systemic therapy?
What dose would you use to treat?
Related Questions
In a patient who underwent cryoablation for early NSCLC, is there a role for giving preemptive further local therapy?
Would you offer SBRT for primary pulmonary adenoid cystic carcinoma in a patient who was medically not a surgical candidate?
How does neoadjuvant chemo-immunotherapy impact your decision on hypofractionation/dose fractionation for locally advanced NSCLC, now getting RT alone?
Would you give durvalumab consolidation to a patient with stage III NSCLC with an STK11 mutation?
Would you consider delaying tarlatamab initiation in a patient with ES SCLC who recently completed RT for CNS disease, given the concern for immune effector cell-associated neurotoxicity syndrome (ICANS)?
Would you give lung SBRT to a patient with bullous pemphigoid on the chest and torso?
Do you restrict the dose rate during treatment delivery to a pacemaker in addition to limiting the Dmax?
Would the presence of an SVC stent affect your decision to offer BID vs once-daily chemoradiation for SCLC?
How do you assess whether a patient will be a good DIBH candidate for lung or abdomen treatments?
Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?